World Journal of Psychiatry
May 19, 2023
Lakshan N Fonseka, Benjamin K.p. Woo
12 citations
With the Food and Drug Administration designation in 2017 of 3,4-methylenedioxymethamphetamine (MDMA) as a breakthrough therapy in post-traumatic stress disorder and psilocybin in treatment-resistant depression, psychedelic drugs have continued to garner the attention of researchers and clinicians for their promise of unmatched, rapid improvement in a multitude of psychiatric conditions....
ACS Chemical Neuroscience
May 17, 2023
Khalyd J Clay, Ava E Axelrod, Christina M MacLaughlin et al.
2 citations
Several naturally occurring molecules exhibit unique potential in treating certain elements of psychiatric illnesses and are being actively pursued in therapeutic development. Among these are molecules termed entheogens, a preferred name for plant-derived compounds that alter human consciousness for religious or spiritual purposes, which are especially important to various Indigenous groups,...
Australian Journal of Chemistry
May 16, 2023
Eliza Milliken, Peter Galettis, Jenny Martin
4 citations
Classic psychedelics such as psilocybin, ketamine and lysergic acid diethylamide (LSD) are 5HT2A serotonin receptor agonists that produce individualised subjective affects. Today, public interest in psychedelic medicine has reached a fervour but the evidence for clinical benefit still lags. Psilocybin and psilocin are tryptophan based alkaloids found worldwide in mushrooms of the genera...
bioRxiv (Cold Spring Harbor Laboratory)
May 12, 2023
S. Parker Singleton, Christopher Timmermann, Andrea I. Luppi et al.
18 citations
preprint
Psychedelics offer a profound window into the functioning of the human brain and mind through their robust acute effects on perception, subjective experience, and brain activity patterns. In recent work using a receptor-informed network control theory framework, we demonstrated that the serotonergic psychedelics lysergic acid diethylamide (LSD) and psilocybin flatten the brain's control energy...
Neuropharmacology
April 2, 2023
Farah Z Zia, Michael H. Baumann, Sean J Belouin et al.
28 citations
Chronic pain is a leading cause of disability, reduced productivity, healthcare seeking behavior, and a contributor to opioid overdose in the United States. For many people, pain can be satisfactorily managed by existing medicines and comprehensive psychosocial treatments. For others, available treatments are either ineffective or not acceptable, due to side effects and concerns about risks....
Journal of Affective Disorders
April 1, 2023
Otto Simonsson, Peter S. Hendricks, Richard Chambers et al.
124 citations
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics,...
Mindfulness
April 1, 2023
Charlotta Simonsson, Richard Chambers, Peter S. Hendricks et al.
15 citations
Previous research has investigated potential synergies between classic psychedelics and meditation practice, but relatively little remains known about the relationship between classic psychedelic experiences and engagement with meditation practice.The purpose of this study was to investigate associations between classic psychedelic experiences and engagement with two popular types of...
Folia Pharmacologica Japonica
March 28, 2023
Daisuke Ibi
1 citation
Major depressive disorder presents a substantial global health burden, and at least 30-40% of patients exhibit treatment resistance to antidepressants. Ketamine, an NMDA receptor antagonist, is used as an anesthetic agent. In 2019, the U.S. Food and Drug Administration (FDA) approved esketamine (the S-enantiomer of ketamine) as a therapeutic agent for treatment-resistant depression; however,...
BMC Psychiatry
March 14, 2023
Rebecca S Ryan, Alex Copello, Andrew P Fox
12 citations
Microdosing psychedelic drugs is a growing phenomenon, but little is known about the experiences surrounding this. Research broadly suggests that people may use psychedelics in an attempt to self-medicate for mental health and wellbeing. However, the precise details, rationale and meaning of such attempts remains unclear, and would benefit from clarification, using tailored experiential...
March 1, 2023
Chase Thompson, Ishrat Husain
Abstract Humans have a long and complicated history with psychedelic compounds. Originally discovered as a component of certain plants and fungi, the psychedelics were widely used by ancient and indigenous peoples for millennia. Contemporary Western society had been largely disconnected from psychedelics but was reintroduced when Albert Hofmann first synthesized D-lysergic acid diethylamide...